



KwikPen®
(tirzepatide) injection
A Lilly Medicine

Available in KwikPen®



Yurpeak is now available in a Multi-dose, pre-filled Kwikpen®

| | Current | New |
|---------------------|-----------------|---|
| | Yurpeak vial | Yurpeak KwikPen |
| Doses per device | 1 dose per vial | 4 doses per KwikPen |
| Needles | Not included | Not included |
| Strengths Available | 2.5 mg, 5 mg | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg |
| Volume per dose | 0.5 mL | 0.6 mL |

Dosing Strengths



Important Information about the KwikPen:

1. Each KwikPen contains **4 fixed doses**. Dispose off the pen after 4 weekly doses or 30 days after first use even though the pen has medicine left in it.
2. The KwikPen must be primed before each dose. To get to the prime position, slowly turn the dose knob until you hear **two clicks** and the **extended line** is shown in the **dose window**.
3. For each weekly injection, the **1** should be showing in the dose window. **1** indicates **one full dose**.
4. To confirm if the injection is complete, check to see if the **0** is showing in the **dose window**.
5. Needles not included.


Prime Position is when the Extended Line is visible in Dose Window



Scan here or visit [obesitypsp.com*](http://obesitypsp.com) in to watch a step-by-step injection demonstration video.

Yurpeak KwikPen contains leftover medicine after 4 injections.¹

- Yurpeak KwikPen is designed to deliver 4 complete doses.
- After the 4th (last) dose, **some leftover medicine will remain** in the KwikPen, and **that is normal**.
- The KwikPen will prevent dialing a full dose after the 4 weekly doses have been given. The **leftover volume does not equal a full dose and is not intended for injection**.
- Yurpeak KwikPen should be discarded 30 days after its first use.




Needle compatibility:

The Yurpeak® KwikPen® is compatible with ISO 11608-2 compliant pen needles from brands such as, BD, Novo Nordisk, and Terumo, in any length and gauge combination. Compliant options include:

- Lengths:** 4 mm, 5 mm, 6 mm, 8 mm, 12.7 mm
- Gauges:** 29G, 31G, 32G, 33G, 34G.²

Not all length/gauge combinations are commercially available. Patients should consult their healthcare provider for recommendations and **guidance on proper injection technique**.

Dosing Schedule and Titration¹



Tirzepatide is started with 2 easy steps

- Initiate with a 2.5 mg dose to start.
- After 4 weeks, the dose should be increased to 5 mg dose.

Additional dose increase

- To achieve individual treatment goals, HCP can increase the dose by 2.5 mg after at least 4 weeks at the current dose.
- Recommended maintenance doses are 5 mg, 10 mg, and 15 mg (maximum dose). Care teams should monitor therapy closely prior to increasing the doses.

Yurpeak® is approved for the following two indications in India:

1. Type 2 Diabetes

Yurpeak® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in addition to other medicinal products for the treatment of diabetes.

2. Weight Management

Yurpeak® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of:
• ≥30 kg/m² (obesity) or
• ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Reference: 1. Yurpeak® (tirzepatide), India Prescribing Information. Updated March 2025 2. Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. *Adv Ther*. 2019;36(11):2986-2996.

This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner and licensed pharmacists only. This material is being provided to healthcare professionals and licensed pharmacists only for their guidance and use. Nothing in this material should be construed as giving medical advice or making recommendations regarding any health-related decision or action. This material can be used by the healthcare professional and licensed pharmacists only, who shall exercise his/her own independent judgement and discretion to disseminate the material. This material has been developed by Cipla under the distribution and promotion license agreement with Eli Lilly. Cipla and Eli Lilly will not be liable for any outcomes due to the inaccurate use of the information provided under this material. Without limitation, the information provided should not replace medical advice received from a healthcare provider or treating doctor.

Yurpeak® is a registered trademark owned by Eli Lilly. Promoted and Distributed by Cipla Limited in India. To be sold by retail under prescription of Endocrinologist or Internal Medicine Specialists only.

For any further information, please contact : Cipla Ltd., Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, India | www.cipla.com



For Tirzepatide Prescribing Information, please scan QR code. Additional information is available on request.